Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

New molecular imaging agent shows high accuracy in detecting liver cancer

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, according to results from a pilot clinical study.

23 Jun 2025

Exploring the intricate epigenetic regulatory network of lncRNAs in hepatocellular carcinoma

A new review published in Genes & Diseases explores the intricate epigenetic regulatory network of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma (HCC), shedding light on the profound impact of DNA methylation, histone modifications, RNA methylation, and microRNAs on lncRNA transcription.

20 Jun 2025

Circular RNAs emerge as key players in hepatitis B-related liver cancer

Hepatitis B virus-induced hepatocellular carcinoma (HCC) remains a major global health burden, and new therapeutic and diagnostic approaches are urgently needed.

20 Jun 2025

Epigenetic dysregulation drives hepatocellular carcinoma development

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide.

19 Jun 2025

Mursla Bio introduces AI Precision Medicine Platform built on organ-specific EV isolation from blood

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling. Mursla Bio is engaging with potential partners to apply its Platform to additional disease areas, biomarker discovery and IV

17 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

Tumor collagen structure may help explain racial disparities in cancer outcomes

In cancer care, accurate tools for predicting whether a tumor will spread (metastasize) can help patients receive the most appropriate treatments.

15 Jun 2025

Rare ovarian tumor found during postmenopausal surgery for pelvic organ prolapse

A new case report was published in Volume 12 of Oncoscience on May 22, 2025, titled "A rare case: Pure Sertoli cell tumor uncovered in atrophic ovary during postmenopausal vault prolapse evaluation."

13 Jun 2025

New data reveals insights into cancer and cardiovascular safety of JAK inhibitors

Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle.

12 Jun 2025

CHAF1B drives lung squamous cell carcinoma progression by repressing SETD7

CHAF1B, a histone chaperone component of the chromatin assembly factor-1 complex, is overexpressed in multiple cancers and linked to tumor progression, but its role in lung squamous-cell carcinoma (LUSC) remained unclear.

11 Jun 2025

Global cancer experts gather in Kenya to improve care across Sub-Saharan Africa

The National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers in the United States-is joining the African Cancer Coalition (ACC) to update cancer treatment recommendations during the American Cancer Society (ACS) 2025 Global Academy Regional Workshop: Sub-Saharan Africa, in Nairobi, Kenya, June 9-11.

10 Jun 2025

Study reveals the genetic underpinnings of a rare and aggressive ovarian cancer

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.

9 Jun 2025

Two patients faced chemo. The one who survived demanded a test to see if it was safe.

JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her.

4 Jun 2025

SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settings

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

4 Jun 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Myeloid cells shape tumor microenvironments and influence cancer progression

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic resistance.

3 Jun 2025

New fluorescent tool tracks cancer cell movement in real time

Cancer cell movement during metastasis is a dynamic process regulated by several different signals. However, the way cells receive, process and respond to these signals has been extremely hard to detect, but is now made easier by a new visualisation tool.

2 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30 May 2025